GLP-1 exendin-4 peptide analogs and uses thereof

US7576050B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Nigel H. Greig · Phoenix, US
• Josephine Egan · Baltimore, US
• Maire Doyle · Baltimore, US
• Harold W. Holloway · Middle River, US
• Tracy Ann Perry · Baltimore, US

Key dates

• Filing date: Jul 30, 2002
• Grant date: Aug 18, 2009
• Expiry date: Apr 24, 2024

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/26
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.